21 May 2009
Inadequate blood pressure control in vast majority of kidney allograft recipients and patients with coronary artery disease with and without comorbidities
J Malyszko, J Malyszko, H Bachorzewska-Gajewska, B Poniatowski, S Dobrzycki, M MysliwiecAnn Transplant 2009; 14(1): 49-49 :: ID: 880377
Abstract
Target blood pressure according to ESH/ESC guidelines should be lower
than 140/90 mm Hg in general population, while in patients with chronic
kidney disease-CKD or diabetes lower than 130/80 mm Hg. Hypertension is widely accepted risk factor for coronary artery disease, chronic heart failure or CKD. In kidney transplant recipient-Tx, prevalence of hypertension is 60-80%. The aim of the study was to assess the prevalence of achieved target blood pressure in 525 patients with coronary artery disease-CAD and 150 prevalent Tx. In CAD population 30% had diabetes and 33% had CKD. In 52% of the patients diabetes and/or CKD was diagnosed, in Tx population 15% had diabetes. Hypertension was diagnosed and treated in 72% in CAD and 90% in Tx. In CAD population without diabetes and CKD only 47% achieved target blood pressure, while in the population with CKD/and/or diabetes only 31%. Patients were treated with ACEi (72%), CCB (28%), diuretics (27%) and b-blockers (89%). In Tx more than 60% required 3 and more hypotensives. Only 40% Tx achieved target BP. In Tx most commonly used hypotensives were CCB (84%), b-blockers (68%), diuretics (51%), ACEi (38%), a-blockers (15%). Despite polytherapy the optimal blood pressure control was not achieved in majority of patients. CAD and Tx had a high prevalence of hypertension, thus they should be treated adequately. More efforts should be put to optimizing blood pressure control, particularly when other co-morbidities are present. Wide use of b-blockers and ACEi under using in Tx population should be noted.
Keywords: Kidney Transplantation
In Press
Original article
Diagnostic Utility of FAR1 Methylation Levels in Hepatocellular Carcinoma Patients Undergoing Liver Transpl...Ann Transplant In Press; DOI: 10.12659/AOT.951568
Original article
Inferior Long-Term Outcome of Fatty Liver Allografts After Orthotopic Liver TransplantationAnn Transplant In Press; DOI: 10.12659/AOT.950589
Database Analysis
Identification and Validation of Liver Transplantation-Induced Acute Lung Injury Biomarkers Using a Bioinfo...Ann Transplant In Press; DOI: 10.12659/AOT.950289
Original article
Survival and Recurrence in Liver Transplant Patients With Intrahepatic Cholangiocarcinoma and Hepatocellula...Ann Transplant In Press; DOI: 10.12659/AOT.950997
Most Viewed Current Articles
24 Aug 2021 : Review article 18,372
Normothermic Machine Perfusion (NMP) of the Liver – Current Status and Future PerspectivesDOI :10.12659/AOT.931664
Ann Transplant 2021; 26:e931664
05 Apr 2022 : Original article 14,731
Impact of Statins on Hepatocellular Carcinoma Recurrence After Living-Donor Liver TransplantationDOI :10.12659/AOT.935604
Ann Transplant 2022; 27:e935604
22 Nov 2022 : Original article 14,244
Long-Term Effects of Everolimus-Facilitated Tacrolimus Reduction in Living-Donor Liver Transplant Recipient...DOI :10.12659/AOT.937988
Ann Transplant 2022; 27:e937988
29 Dec 2021 : Original article 13,752
Efficacy and Safety of Tacrolimus-Based Maintenance Regimens in De Novo Kidney Transplant Recipients: A Sys...DOI :10.12659/AOT.933588
Ann Transplant 2021; 26:e933588






